HIV

Top news of the week from Specialty Pharmacy Times.

Company harnesses CRISPR-based gene editing technology as it enters human clinical trials to treat HIV.

SB239 seeks to reduce the penalty for knowingly exposing sexual partners to HIV to a misdemeanor.

Annually, the Journal of Pharmacy Practice publishes a list of the most significant publications covering infectious disease pharmacotherapy from the previous year.

Findings suggest daily use of Truvada is safe and effective among males aged 15 to 17 years.

Top news of the day from across the health care landscape.

After adjusting for chronological age, the findings showed liver fibrosis was accelerated during peri-menopause compared with pre-menopause.

Top news of the week from Specialty Pharmacy Times.

Accelerated fibrosis in women with a hepatitis C/HIV co-infection begins as early as pre-menopausal years.

The HIV treatment update includes more considerations for coinfected patients and pregnant women than the previously published 2011 guidelines.

The degree of the success for HIV remission vary in different parts of the country.

The findings highlight the role of Tregs in suppressing the immune response.

Approximately 12,000 customers were affected by the breach.

The $2 million grant seeks to help establish guidelines for further development of treatments for HIV.

Findings may lead to new targeted treatment options for HIV infection.

The program is a combination of research, health care services, and community involvement in harm reduction strategies.

West Virginia University program seeks to combat the spread of infectious diseases via injection drug use.

Top news of the day from across the health care landscape.

Top news of the day from across the healthcare landscape.

HIV rebound detected within 1 day before delivery in 50% of study participants.

For HIV-mixed status couples attempting conception, prior effective antiretroviral therapy (ART) can profoundly reduce the risk of sexual transmission of the disease, according to a report published in the Morbidity and Mortality Weekly Report.

Odefsey label updated to include updated data from clinical trials examining patients who switched from tenofovir disoproxil fumarate-based regimens.

Changes include additional trial data in virologically-suppressed adults with HIV-1 infection.

Younger patients with HIV have competing needs that distract them from fully engaging in care.

Adolescents and young adults aged 13 to 24 years old are particularly vulnerable to HIV infection, representing 21% of newly infected individuals in most recent data.

Prolonged delay in antiretroviral treatment among patients necessitate scrutinization of the current guidelines for HIV therapy.

Prior studies suggest that as many as two-thirds of all older HIV-positive Americans have experienced stigma due to the disease and their age.

Stigma partially drives poorer health outcomes in patients with HIV.

Funding will be spread throughout several mentorship programs for youths with HIV to help navigate adult care.

According to new findings, home-based HIV testing kits could be an effective strategy to reach individuals who have never been tested.